Literature DB >> 1721488

Image analysis quantitation of immunoreactive retinoblastoma protein in human thyroid neoplasms with a streptavidin-biotin-peroxidase staining technique.

J Figge1, G Bakst, D Weisheit, O Solis, J S Ross.   

Abstract

Studies investigating the molecular pathogenesis of common thyroid neoplasms have shown altered expression and/or structure of proto-oncogenes, G-proteins, and growth factors. Growth suppressor genes, genomic DNA segments that code for proteins believed to function as growth suppressors, have not been evaluated for a potential role in the pathogenesis of thyroid neoplasms. The retinoblastoma gene (RB1) maps to chromosome 13q14 and encodes a 110 kilodalton variably phosphorylated nuclear protein (Rb) that functions as a growth suppressor in a wide variety of human tissues. The frequent association of Rb protein loss with multiple neoplasms has prompted the authors to apply a specific and rapid immunohistochemical technique using streptavidin-biotin-peroxidase technology evaluated by image analysis that can be used to quantitate the level of immunoreactive Rb protein (iRb) in thyroid neoplasms. In utilizing streptavidin-biotin technology for nuclear iRb detection, artifacts that can be associated with the use of avidin such as nonspecific binding at physiologic pH and nonspecific complex formation with cellular components including chromatin are avoided. By this method, positive nuclear staining for iRb in the follicular cells of three follicular adenomas and in CV-1 control cells known to express Rb was demonstrated. Two papillary carcinomas, two medullary carcinomas and a SAOS-2 cell line known to produce a defective form of Rb stained at significantly lower levels (P less than .001). The authors conclude that the streptavidin-biotin-peroxidase staining technique evaluated by image analysis is a sensitive and specific detection system for nuclear iRb studies; has significant advantages over previously used techniques; and that thyroid neoplasms may variably express iRb which may, in part, reflect their variable pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1721488      PMCID: PMC1886450     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  35 in total

1.  Altered expression of the retinoblastoma gene product in human sarcomas.

Authors:  W G Cance; M F Brennan; M E Dudas; C M Huang; C Cordon-Cardo
Journal:  N Engl J Med       Date:  1990-11-22       Impact factor: 91.245

2.  THE PROPERTIES OF STREPTAVIDIN, A BIOTIN-BINDING PROTEIN PRODUCED BY STREPTOMYCETES.

Authors:  L CHAIET; F J WOLF
Journal:  Arch Biochem Biophys       Date:  1964-07-20       Impact factor: 4.013

Review 3.  Protein kinases and protooncogenes: biochemical regulators of the eukaryotic cell cycle.

Authors:  R S Freeman; D J Donoghue
Journal:  Biochemistry       Date:  1991-03-05       Impact factor: 3.162

4.  Adenovirus E1a prevents the retinoblastoma gene product from complexing with a cellular transcription factor.

Authors:  L R Bandara; N B La Thangue
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

5.  The E2F transcription factor is a cellular target for the RB protein.

Authors:  S P Chellappan; S Hiebert; M Mudryj; J M Horowitz; J R Nevins
Journal:  Cell       Date:  1991-06-14       Impact factor: 41.582

Review 6.  A genetic model for colorectal tumorigenesis.

Authors:  E R Fearon; B Vogelstein
Journal:  Cell       Date:  1990-06-01       Impact factor: 41.582

Review 7.  Oncogenes and growth factors in thyroid carcinogenesis.

Authors:  A G Frauman; A C Moses
Journal:  Endocrinol Metab Clin North Am       Date:  1990-09       Impact factor: 4.741

8.  Point mutations of ras oncogenes are an early event in thyroid tumorigenesis.

Authors:  H Namba; S A Rubin; J A Fagin
Journal:  Mol Endocrinol       Date:  1990-10

9.  Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas.

Authors:  H J Xu; S X Hu; P T Cagle; G E Moore; W F Benedict
Journal:  Cancer Res       Date:  1991-05-15       Impact factor: 12.701

10.  Retinoblastoma cancer suppressor gene product is a substrate of the cell cycle regulator cdc2 kinase.

Authors:  B T Lin; S Gruenwald; A O Morla; W H Lee; J Y Wang
Journal:  EMBO J       Date:  1991-04       Impact factor: 11.598

View more
  4 in total

1.  Loss of heterozygosity of the retinoblastoma gene in liver cirrhosis accompanying hepatocellular carcinoma.

Authors:  K Ashida; Y Kishimoto; K Nakamoto; K Wada; G Shiota; Y Hirooka; Y Kamisaki; T Itoh; H Kawasaki
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

Review 2.  Looking at Thyroid Cancer from the Tumor-Suppressor Genes Point of View.

Authors:  Sadegh Rajabi; Catherine Alix-Panabières; Arshia Sharbatdar Alaei; Raziyeh Abooshahab; Heewa Shakib; Mohammad Reza Ashrafi
Journal:  Cancers (Basel)       Date:  2022-05-17       Impact factor: 6.575

3.  Reduced Retinoblastoma Protein Expression Is Associated with Decreased Patient Survival in Medullary Thyroid Cancer.

Authors:  Anisley Valenciaga; Elizabeth G Grubbs; Kyle Porter; Paul E Wakely; Michelle D Williams; Gilbert J Cote; Vasyl V Vasko; Motoyasu Saji; Matthew D Ringel
Journal:  Thyroid       Date:  2017-12       Impact factor: 6.568

4.  Anomalous retinoblastoma protein expression in Sternberg-Reed cells in Hodgkin's disease: a comparative study with p53 and Ki67 expression.

Authors:  M Sánchez-Beato; J C Martínez-Montero; T A Doussis-Anagnostopoulou; K C Gatter; J García; J F García; E LLoret; M A Piris
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.